S'abonner

Comparable efficacy and safety of treatment with biological agents etanercept and anakinra in children with Juvenile Idiopathic Arthritis in Latvia - 19/04/08

Doi : 10.1016/j.jbspin.2008.01.008 
D. Guseinova a, V. Stanevicha a, R. Shantere b, D. Berzina b, A. Schegolevs b, D. Balode b, A. Uruma b
a Riga Stradins University 
b Childrens' Clinical University Hospital 

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

AB06

Abstract

Background

The introduction of biologics holds great promise in the management of the two, often most aggressive and challenging forms of Juvenile Idiopathic Arthritis (JIA) – polyarticular and systemic onset or Still`s disease. JIA is not a single disease and treatment approach varies between types. Recently it has been demonstrated that treatment with anti TNF agent etanercept has a major beneficial effect on children with refractory polyarthritis [1]. Since IL-1 has been shown to be an important cytokine in the pathogenesis of systemic arthritis, therapies directed against this cytokine has been shown to be effective for this form of JIA [2].

Objectives

To evaluate treatment efficacy and safety with two different biologics: anti TNF etanercept and anti IL-1 anakinra in patients with polyarthritis and Still`s disease.

Methods and materials

Data from 32 JIA patients (30 serenegative polyarthritis and 2 Still`s disease), aged 4 to 18 years, receiving treatment with biological agents, were obtained. JIA diagnosis and disease type were confirmed according to the ILAR classification criteria of JIA [3].

Patients unresponsive to prior MTX therapy, were started with combination etanercept (s/c twice a week in a dose 0.4 mg/kg) and methotrexate (MTX) (once a week in a dose 10-15 mg/m2) with the evaluation of clinical response at the period of 3 and 6 months.

The assesment of therapeutical response was made using criteria of preliminary definition of improvement in JIA proposed by Giannini et al. [4].

Results

One patient with polyarthritis showed intolerance to etanercept, due to which the drug was discontinued, while 29 patients with polyarticular JIA (14 boys and 15 girls) showed improvement after the combination etanercept and MTX treatment, according to the global physician assesment of the severity of disease (p<0.01), the global assesment of overall well-being determined by the parent (p<0.01) and by the pain severity scale (p<0.01).

Due to the lack of response to etanercept in 2 pts with systemic arthritis, treatment was switched to anakinra (in combination with MTX), which showed good therapeutic response and remission was achieved.

The clinical and laboratory evaluation of the patients showed decrease in the number of affected joints and decrease in CRP level (p<0.05).

Overall in our experience treatment with biologics, except for mild local injection site reactions in some patients, was not connected with the occurence of any severe side effects, opportunistic infections or autoimmune reactions.

Conclusions

1) Anti TNF treatment is effective in patients with polyarticular course of JIA, resistant to MTX therapy 2) Patients with systemic arthritis who fail to respond to anti TNF, are improving on anti IL-1 treatment with anakinra, that is according to the literature data 3) Treatment with biologics shows good safety profile 4) The use of the Biologics Registry data is essential to establish the longer-term clinical effectiveness of biologics, as well as their potential for toxicity to help further define the most appropriate use of these agents.

Le texte complet de cet article est disponible en PDF.

Plan


© 2008  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 75 - N° 2

P. 244 - mars 2008 Retour au numéro
Article précédent Article précédent
  • Proinflammatory cytokines (IL-15, TNFα, IL-6 and IL-1β) in rheumatoid arthritis bone marrow preferentially promote activation of T-cells
  • E. Warnawin, A. Radzikowska, T. Burakowski, W. Maślinski
| Article suivant Article suivant
  • Antimicrobal therapy resistance in group A beta haemolytic Streptococcus infection and rheumatic fever
  • D. Zavadska, L. Drukaļska, D. Bērziņa, D. Gardovska, V. Stanevicha, E. Miklaševičs

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.